Compass Pathways has stronger COMP360 data, but can psilocybin treatment scale?
Find out how Compass Pathways’ COMP360 Phase 3 data could shape regulated psilocybin treatment for depression.
Pharma & Biotech
Pharma & Biotech
Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
Find out how Optimi Health’s UK psilocybin export could reshape psychedelic trial supply and what risks remain for Phase 2 research.